CN108371326A - 一种降血糖的功能性组合物 - Google Patents
一种降血糖的功能性组合物 Download PDFInfo
- Publication number
- CN108371326A CN108371326A CN201810294554.5A CN201810294554A CN108371326A CN 108371326 A CN108371326 A CN 108371326A CN 201810294554 A CN201810294554 A CN 201810294554A CN 108371326 A CN108371326 A CN 108371326A
- Authority
- CN
- China
- Prior art keywords
- parts
- function
- blood sugar
- isoleucine
- valine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 230000003178 anti-diabetic effect Effects 0.000 title claims abstract description 7
- 239000003472 antidiabetic agent Substances 0.000 title claims abstract description 7
- 239000008280 blood Substances 0.000 claims abstract description 63
- 210000004369 blood Anatomy 0.000 claims abstract description 63
- 235000000346 sugar Nutrition 0.000 claims abstract description 39
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 32
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 23
- 244000045195 Cicer arietinum Species 0.000 claims abstract description 22
- 235000010523 Cicer arietinum Nutrition 0.000 claims abstract description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 21
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 16
- OSCCDBFHNMXNME-WDCZJNDASA-N (2s,3s,4r)-2-amino-4-hydroxy-3-methylpentanoic acid Chemical compound C[C@@H](O)[C@@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-WDCZJNDASA-N 0.000 claims abstract description 16
- 239000004475 Arginine Substances 0.000 claims abstract description 16
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 16
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 16
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 16
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 16
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 16
- OSCCDBFHNMXNME-UHFFFAOYSA-N gamma-hydroxyisoleucine Natural products CC(O)C(C)C(N)C(O)=O OSCCDBFHNMXNME-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960000310 isoleucine Drugs 0.000 claims abstract description 16
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000001603 reducing effect Effects 0.000 claims abstract description 16
- 239000004474 valine Substances 0.000 claims abstract description 16
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 15
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 15
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000004279 alanine Nutrition 0.000 claims abstract description 15
- 239000004471 Glycine Substances 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 229940024606 amino acid Drugs 0.000 claims abstract description 10
- 235000001014 amino acid Nutrition 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 8
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 8
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 5
- 230000002195 synergetic effect Effects 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- -1 citrulling Chemical compound 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 abstract description 23
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 11
- 239000004615 ingredient Substances 0.000 abstract description 7
- YEGAKLYOVHUQIJ-WHFBIAKZSA-N N-hydroxy-L-isoleucine Chemical class CC[C@H](C)[C@H](NO)C(O)=O YEGAKLYOVHUQIJ-WHFBIAKZSA-N 0.000 abstract 1
- 239000008103 glucose Substances 0.000 description 35
- 230000006870 function Effects 0.000 description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 108010011485 Aspartame Proteins 0.000 description 7
- 241000220223 Fragaria Species 0.000 description 7
- 239000000605 aspartame Substances 0.000 description 7
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 7
- 235000010357 aspartame Nutrition 0.000 description 7
- 229960003438 aspartame Drugs 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019705 chickpea protein Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了一种降血糖的功能性组合物，功效成分由鹰嘴豆肽、4‑羟基异亮氨酸、丙氨酸、精氨酸、亮氨酸、异亮氨酸、缬氨酸、瓜氨酸、色氨酸、甘氨酸和γ‑氨基丁酸，各组份按其重量份数计鹰嘴豆肽20‑40份、4‑羟基异亮氨酸10‑40份、丙氨酸1‑10份、精氨酸1‑10份、亮氨酸1‑10份、异亮氨酸1‑10份、缬氨酸1‑10份、瓜氨酸1‑10份、色氨酸1‑10份、甘氨酸1‑10份和γ‑氨基丁酸1‑10份；所述食品通过鹰嘴豆肽与氨基酸的合理配伍，能够有效辅助调节人体血糖，是成分和含量稳定均衡、功能明晰的降糖功能食品，可用于预防糖尿病、减少糖尿病患者的用药量，改善糖尿病患者高血糖的状况。
Description
技术领域
本发明涉及食品加工领域，尤其是一种降血糖的功能性组合物。
背景技术
糖尿病已成为21世纪最重要的医学问题。据统计，2013年全球糖尿病患者达3.82亿，其中我国患者近0.98亿，居世界首位。预计10年内，由糖尿病造成的死亡总数将增加50％以上，将成为全球第七大死亡原因，到2035年糖尿病患者将达5.92亿。尽管目前已有多种糖尿病治疗药物，随着患者数量的激增，传统药物供应不足、长期服用引发的副作用等不足日益突显。
功能性食品因具有调节机体代谢、提高免疫力、降血糖以及降血脂等功能，被用于多种疾病的预防、改善和辅助治疗。然而，目前我国功能性食品多以药食同源的材料或具有主要活性成分的材料为主要原料，存在成分和含量不明晰，且原料质量差异较大，容易造成针对性不强、营养摄取不均衡等潜在危害。因此成分和含量稳定均衡、功能明晰的降糖功能性食品具有重要的应用价值。
发明内容
本发明所要解决的技术问题在于提供鹰嘴豆肽和氨基酸协同作用的新用途。
本发明所要解决的另一技术问题在于提供一种降血糖的功能性组合物。
为解决上述技术问题，本发明的技术方案是：
鹰嘴豆肽和氨基酸协同作用在制备降血糖的功能性食品或药品方面的应用。
优选的，上述鹰嘴豆肽和氨基酸协同作用的应用，所述氨基酸为4-羟基异亮氨酸、丙氨酸、精氨酸、亮氨酸、异亮氨酸、缬氨酸、瓜氨酸、色氨酸、甘氨酸和γ-氨基丁酸。
一种具有降糖作用的功能性组合物，功效成分由鹰嘴豆肽、4-羟基异亮氨酸、丙氨酸、精氨酸、亮氨酸、异亮氨酸、缬氨酸、瓜氨酸、色氨酸、甘氨酸和γ-氨基丁酸，各组份按其重量份数计鹰嘴豆肽20-40份、4-羟基异亮氨酸10-40份、丙氨酸1-10份、精氨酸1-10份、亮氨酸1-10份、异亮氨酸1-10份、缬氨酸1-10份、瓜氨酸1-10份、色氨酸1-10份、甘氨酸1-10份和γ-氨基丁酸1-10份。
优选的，上述具有降糖作用的功能性组合物，各组份按其重量份数计鹰嘴豆肽20份、4-羟基异亮氨酸30份、丙氨酸6份、精氨酸6份、亮氨酸5份、异亮氨酸5份、缬氨酸5份、瓜氨酸6份、色氨酸5份、甘氨酸5份和γ-氨基丁酸7份。
优选的，上述具有降糖作用的功能性组合物，还包括调味剂。
优选的，上述具有降糖作用的功能性组合物，所述调味剂为阿斯巴甜、木糖醇、柠檬酸、草莓香精一种或任意组合。
上述具有降糖作用的功能性组合物，将组方中各组分按特定配比混合即可制备得到。
上述具有降糖作用的功能性组合物用水冲调食用或直接口服。
本发明的有益效果是：
本发明所述降血糖功能性组合物，通过鹰嘴豆肽与氨基酸的合理配伍，能够有效辅助调节人体血糖，是成分和含量稳定均衡、功能明晰的降糖功能食品，可用于预防糖尿病、减少糖尿病患者的用药量，改善糖尿病患者高血糖的状况。
具体实施方式
下面结合具体实施例对本发明所述技术方案作进一步的说明，本发明所述各组分均为市购商品。
实施例1
将鹰嘴豆肽20g、4-羟基异亮氨酸30g、丙氨酸6g、精氨酸6g、亮氨酸5g、异亮氨酸5g、缬氨酸5g、瓜氨酸6g、色氨酸5g、甘氨酸5g、γ-氨基丁酸7g、阿斯巴甜0.1g、草莓香精0.001g，投入到三维混合机中混合均匀，得降血糖功能性食品。经质检部检验保证产品的感官指标，理化指标和微生物指标均符合国家标准。用温水溶解后口服，每日3次，每次2.5g/50kg。
实施例2
将鹰嘴豆肽20g、4-羟基异亮氨酸30g、丙氨酸1g、精氨酸3g、亮氨酸2g、异亮氨酸5g、缬氨酸5g、瓜氨酸2g、色氨酸6g、甘氨酸5g、γ-氨基丁酸7g、木糖醇0.1g、柠檬酸0.1g、草莓香精0.001g，制备方法同实施例1。
实施例3
将鹰嘴豆肽20g、4-羟基异亮氨酸40g、丙氨酸6g、精氨酸10g、亮氨酸8g、异亮氨酸8g、缬氨酸8g、瓜氨酸6g、色氨酸8g、甘氨酸8g、γ-氨基丁酸10g、阿斯巴甜0.2g、柠檬酸0.2g、草莓香精0.002g，制备方法同实施例1。
实施例4
将鹰嘴豆肽40g、4-羟基异亮氨酸10g、丙氨酸10g、精氨酸1g、亮氨酸10g、异亮氨酸10g、缬氨酸1g、瓜氨酸9g、色氨酸1g、甘氨酸2g、γ-氨基丁酸1g、阿斯巴甜0.2g、柠檬酸0.2g、草莓香精0.002g，制备方法同实施例1。
上述实施例1-4之一所述各组分用量按照相同比例增加或减少，所得各组分的重量份数关系均属于本发明的保护范围。
组方分析：
鹰嘴豆肽，存在于鹰嘴豆中，是经特定的蛋白水解酶通过对鹰嘴豆蛋白的水解作用得到的一类小分子肽的化合物，这些短肽氨基酸含有多种必需氨基酸，具有降血糖、抗氧化和抗肿瘤等功能。
4-羟基异亮氨酸具有葡萄糖浓度依赖的促进胰岛素分泌的活性，即仅血糖浓度高于正常值时，4-羟基异亮氨酸才具有促进胰岛素分泌的活性且该活性随血糖浓度的升高而增强，这是其他治疗糖尿病药物不可比拟的。此外，4-羟基异亮氨酸还具有增强肌细胞对血糖吸收、促进脂肪代谢、降血脂以及保护肝功能等作用。
丙氨酸具有调节血糖代谢，增强免疫能力，增加体能，提供能量，消除疲劳的功能。
精氨酸具有刺激胰岛素分泌，调节血糖平衡；提高机体免疫力；平衡血压，增强血流，改善心脑供血的功能。
亮氨酸具有的为机体提供能量，调节血糖及机体免疫功能的功效。
异亮氨酸具有为机体提供能量，调节脂肪和血糖代谢，缓解低血糖造成的头痛的功能
缬氨酸具有的调节血糖，提供机体所需能量，保护肝脏功能
瓜氨酸具有平衡血糖水平，保持正常胆固醇水平；清除自由基，抗衰老、提高免疫系统功能的功效。
色氨酸具有的调节血糖和脂类代谢，降低血压和血脂，促进蛋白质合成的功能。
甘氨酸具有调节血糖代谢，具有保护心肌和肝脏的功能。
γ-氨基丁酸具有调节血糖和免疫功能，改善神经系统机能，提高脑活力的功能。
各组分协同作用，能够有效辅助调节人体血糖。
采用实施例1所述降血糖功能性食品，按照中华人民共和国国家卫生和计划生育委员会《保健食品检验与评价技术规范(2003版)》的规定进行功能试验和试验结果评价。
一、辅助降血糖试验
1、对高血糖模型小鼠空腹血糖的影响
选取健康小鼠禁食24小时后，给予四氧嘧啶，5-7天后禁食3-5小时，测血糖，血糖值为10-25mmol/L为高血糖模型小鼠。对高血糖模型小鼠和健康小鼠分别进行灌胃，灌胃剂量为0-500mg/kg.bw，以相同灌胃剂量的对照1、对照2和对照3为对照，持续30天。然后测定空腹血糖值，比较各组小鼠血糖值及血糖下降百分率。血糖下降百分率＝(试验前血糖值-试验后血糖值)/试验前血糖值×100％。实施例1所述降血糖功能性食品的灌胃剂量为0-500mg/kg.bw，测定试验前后血糖差异，结果如表1-表4所示。在试验过程，未发现受试小鼠异常。对照1和对照2 50mg/kg.bw和500mg/kg.bw剂量组高血糖小鼠血糖略有下降(P≤0.05)，但对照3对血糖无任何作用，而本发明所述降血糖功能性食品50mg/kg.bw和500mg/kg.bw剂量组高血糖小鼠血糖下降百分率的显著性远远高于对照1和对照2组(P≤0.05)。但本发明所述降血糖功能性食品对健康动物空腹血糖无显著影响(表5)。
对照1
将鹰嘴豆肽20g、阿斯巴甜0.1g、草莓香精0.001g，投入到三维混合机中混合均匀。
对照2
将4-羟基异亮氨酸30g、阿斯巴甜0.1g、草莓香精0.001g，投入到三维混合机中混合均匀。
对照3
将丙氨酸6g、精氨酸6g、亮氨酸5g、异亮氨酸5g、缬氨酸5g、瓜氨酸6g、色氨酸5g、甘氨酸5g、γ-氨基丁酸7g、阿斯巴甜0.1g、草莓香精0.001g，投入到三维混合机中混合均匀。
表1按对照1配制的成分对高血糖模型动物空腹血糖的影响
表2按对照2配制的成分对高血糖模型动物空腹血糖的影响
表3按对照3配制的成分对高血糖模型动物空腹血糖的影响
表4按实施例1配制的成分对高血糖模型动物空腹血糖的影响
表5实施例1产品对健康动物空腹血糖的影响
2、对高血糖模型动物糖耐量的影响
选取健康小鼠禁食24小时后，给予四氧嘧啶，5-7天后禁食3-5小时，测血糖，血糖值为10-25mmol/L为高血糖模型小鼠。对高血糖模型小鼠进行灌胃，灌胃剂量为0-500mg/kg.bw，以相同灌胃剂量的对照1、对照2和对照3为对照，15-20分钟后经口给予葡萄糖2.0g/kg，测定给予葡萄糖0、0.5、2小时的血糖值，观察模型各时间点血糖曲线下面积的变化。血糖曲线下面积＝0.25×(0小时血糖值+4×0.5小时血糖值+3×2小时血糖值)，结果如表6-9所示。对照2 50mg/kg.bw和500mg/kg.bw剂量组高血糖小鼠血糖曲线下面积与未灌胃组略有差异(P≤0.05)，对照1和对照3对此无任何作用。本产品50mg/kg.bw和500mg/kg.bw剂量组高血糖小鼠血糖曲线下面积与对照1、对照2和对照3差异显著，且远高于对照1(P≤0.05)。表明本发明所述降血糖功能性食品的对高血糖小鼠的糖耐量有显著影响。试验过程中未见受试小鼠异常，结果见表6-9。
表6对照1对高血糖模型动物糖耐量的影响
表7对照2对高血糖模型动物糖耐量的影响
表8对照3对高血糖模型动物糖耐量的影响
表9实施例1对高血糖模型动物糖耐量的影响
可见，经口灌胃给予高血糖小鼠50mg/kg.bw和500mg/kg.bw剂量的本发明所述降血糖功能性食品30天，能够提高高血糖小鼠血糖下降百分率，表明对动物具有辅助降血糖功能。
上述参照实施例对该一种功能性组合物进行的详细描述，是说明性的而不是限定性的，可按照所限定范围列举出若干个实施例，因此在不脱离本发明总体构思下的变化和修改，应属本发明的保护范围之内。
Claims (6)
1.鹰嘴豆肽和氨基酸协同作用在制备降血糖的功能性食品或药品方面的应用。
2.根据权利要求1所述的鹰嘴豆肽和氨基酸协同作用的应用，其特征在于：所述氨基酸为4-羟基异亮氨酸、丙氨酸、精氨酸、亮氨酸、异亮氨酸、缬氨酸、瓜氨酸、色氨酸、甘氨酸和γ-氨基丁酸。
3.一种具有降糖作用的功能性组合物，其特征在于：功效成分由鹰嘴豆肽、4-羟基异亮氨酸、丙氨酸、精氨酸、亮氨酸、异亮氨酸、缬氨酸、瓜氨酸、色氨酸、甘氨酸和γ-氨基丁酸，各组份按其重量份数计鹰嘴豆肽20-40份、4-羟基异亮氨酸10-40份、丙氨酸1-10份、精氨酸1-10份、亮氨酸1-10份、异亮氨酸1-10份、缬氨酸1-10份、瓜氨酸1-10份、色氨酸1-10份、甘氨酸1-10份和γ-氨基丁酸1-10份。
4.根据权利要求3所述的具有降糖作用的功能性组合物，其特征在于：各组份按其重量份数计鹰嘴豆肽20份、4-羟基异亮氨酸30份、丙氨酸6份、精氨酸6份、亮氨酸5份、异亮氨酸5份、缬氨酸5份、瓜氨酸6份、色氨酸5份、甘氨酸5份和γ-氨基丁酸7份。
5.根据权利要求3所述的具有降糖作用的功能性组合物，其特征在于：还包括调味剂。
6.根据权利要求5所述的具有降糖作用的功能性组合物，其特征在于：所述调味剂为阿斯巴甜、木糖醇、柠檬酸、草莓香精一种或任意组合。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017113336264 | 2017-12-14 | ||
| CN201711333626 | 2017-12-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108371326A true CN108371326A (zh) | 2018-08-07 |
| CN108371326B CN108371326B (zh) | 2021-08-20 |
Family
ID=63031895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810294554.5A Active CN108371326B (zh) | 2017-12-14 | 2018-03-30 | 一种降血糖的功能性组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108371326B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113170896A (zh) * | 2021-04-08 | 2021-07-27 | 南京北极光生物科技有限公司 | 一种含γ-氨基丁酸和瓜氨酸的组合物及其在缓解压力和改善睡眠上的应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1386862A (zh) * | 2002-07-09 | 2002-12-25 | 邹远东 | 酶法制得鹰嘴豆蛋白多肽的方法和用途 |
| CN1611487A (zh) * | 2003-10-27 | 2005-05-04 | 成都华高天然产物有限责任公司 | 一种从葫芦巴中提取4－羟基异亮氨酸制品的新方法 |
| CN1678331A (zh) * | 2002-05-10 | 2005-10-05 | Tsi公司 | 胡芦巴种子生物活性组合物及提取该组合物的方法 |
| CN1921881A (zh) * | 2003-10-27 | 2007-02-28 | 因诺迪亚公司 | 羟基化氨基酸用于治疗糖尿病的用途 |
| CN101142988A (zh) * | 2006-09-13 | 2008-03-19 | 范旻 | 一种无糖型强化元素鹰嘴豆粉 |
| CN102028036A (zh) * | 2009-09-24 | 2011-04-27 | 陈漫霞 | 一种以鹰嘴豆制备多肽饮料的方法 |
| CN105622715A (zh) * | 2016-04-05 | 2016-06-01 | 中国科学院新疆理化技术研究所 | 一种鹰嘴豆多肽粉的快速制备方法及其应用 |
-
2018
- 2018-03-30 CN CN201810294554.5A patent/CN108371326B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1678331A (zh) * | 2002-05-10 | 2005-10-05 | Tsi公司 | 胡芦巴种子生物活性组合物及提取该组合物的方法 |
| CN1386862A (zh) * | 2002-07-09 | 2002-12-25 | 邹远东 | 酶法制得鹰嘴豆蛋白多肽的方法和用途 |
| CN1611487A (zh) * | 2003-10-27 | 2005-05-04 | 成都华高天然产物有限责任公司 | 一种从葫芦巴中提取4－羟基异亮氨酸制品的新方法 |
| CN1921881A (zh) * | 2003-10-27 | 2007-02-28 | 因诺迪亚公司 | 羟基化氨基酸用于治疗糖尿病的用途 |
| CN101142988A (zh) * | 2006-09-13 | 2008-03-19 | 范旻 | 一种无糖型强化元素鹰嘴豆粉 |
| CN102028036A (zh) * | 2009-09-24 | 2011-04-27 | 陈漫霞 | 一种以鹰嘴豆制备多肽饮料的方法 |
| CN105622715A (zh) * | 2016-04-05 | 2016-06-01 | 中国科学院新疆理化技术研究所 | 一种鹰嘴豆多肽粉的快速制备方法及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| 刘艳等: "鹰嘴豆肽组成分析及对HepG2细胞葡萄糖消耗影响的研究 ", 《食品工业》 * |
| 王觐等: "不同氨基酸对小鼠血糖影响的研究 ", 《军医进修学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113170896A (zh) * | 2021-04-08 | 2021-07-27 | 南京北极光生物科技有限公司 | 一种含γ-氨基丁酸和瓜氨酸的组合物及其在缓解压力和改善睡眠上的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108371326B (zh) | 2021-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020172523A (ja) | ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び／又は刺激におけるその使用 | |
| CN106360310A (zh) | 一种降低餐后血糖的组合物及其应用 | |
| US20160360776A1 (en) | Dietary supplement compositions | |
| CN102438642A (zh) | 包含绿茶提取物的组合物 | |
| EP3141255A1 (en) | Memory improving composition, preparation method and use thereof | |
| CN113398144B (zh) | 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用 | |
| KR20150005430A (ko) | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 | |
| JP2017523173A (ja) | ザクロ濃縮物を有効成分として含む肌改善用組成物 | |
| CN105495582A (zh) | 一款抗疲劳、促恢复的保健食品氨基酸组合物 | |
| KR100770775B1 (ko) | 면역증강을 위한 기능성 음료 및 그 제조방법 | |
| CN103704711B (zh) | 一种具有抗疲劳保健功能冲剂 | |
| WO2007007993A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea l. var. edulis extract | |
| CN108371326A (zh) | 一种降血糖的功能性组合物 | |
| CN109589400B (zh) | 一种具有神经保护功效的组合物 | |
| CN107998370B (zh) | 一种可增强机体运动能力且缓解运动疲劳的组合物 | |
| BUTNARIU | Biochemical aspects of diabetes mellitus | |
| CN109198347A (zh) | 一种大豆肽固体饮料及其应用 | |
| US20110318333A1 (en) | Novel non-toxic composition and method of using such for treating a degenerative or an immune system-related disease | |
| CN108402473B (zh) | 一种具有改善记忆功能的用于口服的脑多肽组合物 | |
| CN101214052B (zh) | 一种具有缓解体力疲劳、增强免疫功能的保健食品 | |
| Yonei et al. | A placebo-controlled, randomized, single-blind, parallel-group comparative study to evaluate the anti-glycation effect of a functional soymilk beverage supplemented with rice bran/rice bran oil | |
| CN101095547A (zh) | 活性微生物饮料 | |
| CN102885305A (zh) | 一种增强免疫力的保健食品组合物及其制备方法 | |
| JP6378926B2 (ja) | 血糖値低下用組成物 | |
| CN110404029B (zh) | 一种具有降血糖功效的组合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |